Localized Prostate Cancer Clinical Trial
Official title:
Safety and Efficacy Study of Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer: a Randomized Controlled Clinical Trial
The aim of this trial is to compare the safety outcomes of Hypofractionated postprostatectomy radiotherapy (HYPORT) and Conventionally fractionated postprostatectomy radiotherapy(COPORT) in treating patients with localized prostate cancer. Accumulating evidence has proven the safety and feasibility of HYPORT for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of HYPORT is still on its way. It is not yet known whether giving HYPORT(57.5-65 Gy in 23-26 daily fractions of 2.5 Gy ) with or COPORT may work better in treating patients with prostate cancer.
The present study will be conducted as a prospective, open-label, two arms clinical trial. Patients with pathologically confirmed prostate cancer and completed radical resection of prostate cancer, will be randomized in a 1:1 ratio between arm A (COPORT) and arm B (HYPORT). The patients in arm A will receive COPORT(66-74 Gy in 33-37 daily fractions of 2 Gy ). The patients in arm B will receive HYPORT(57.5-65 Gy in 23-26 daily fractions of 2.5 Gy ). After completion of study treatment, patients were followed up once a month for the first 3 months and once every 3 months after 3 months for a total of 5 years. The primary endpoints of the study are toxicities parameters.The secondary endpoints include ,progression-free survival (PFS),medical economics,quality of life (QoL), overall survival (OS)and prostate cancer-specific survival period. The progression-free survival (PFS) including biochemical progression-free survival (bPFS), and radiological progression-free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03996005 -
MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
|
N/A | |
| Withdrawn |
NCT02159690 -
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
|
Phase 2 | |
| Completed |
NCT00196781 -
Treatment Decision Making in Early-Stage Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT03821246 -
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
|
Phase 2 | |
| Active, not recruiting |
NCT03814252 -
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer
|
N/A | |
| Completed |
NCT01931046 -
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01714219 -
Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy
|
N/A | |
| Active, not recruiting |
NCT03315754 -
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
|
Phase 2 | |
| Recruiting |
NCT05010343 -
Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06051942 -
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
|
N/A | |
| Completed |
NCT02297386 -
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06117059 -
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
|
N/A | |
| Withdrawn |
NCT04225299 -
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT06054867 -
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
|
N/A | |
| Active, not recruiting |
NCT02435472 -
Active Surveillance Exercise Clinical Trial
|
N/A | |
| Completed |
NCT00717613 -
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
|
N/A | |
| Completed |
NCT02662673 -
Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device
|
N/A | |
| Recruiting |
NCT05155046 -
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
|
Phase 2 | |
| Completed |
NCT01902680 -
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.
|
Phase 2 | |
| Recruiting |
NCT00651417 -
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
|
Phase 2 |